Pliant Therapeutics Inc Ordinary Shares PLRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PLRX is a good fit for your portfolio.
News
-
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
-
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $15.28
- Day Range
- $15.39–15.70
- 52-Week Range
- $11.29–24.74
- Bid/Ask
- $15.64 / $15.74
- Market Cap
- $942.29 Mil
- Volume/Avg
- 22,260 / 372,741
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3,678.63
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 158
- Website
- https://www.pliantrx.com
Comparables
Valuation
|
Metric
|
PLRX
|
CBAY
|
DYN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.11 | 12.65 | 5.04 |
Price/Sales | 3,678.63 | 111.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PLRX
CBAY
DYN
Financial Strength
|
Metric
|
PLRX
|
CBAY
|
DYN
|
|---|---|---|---|
Quick Ratio | 15.95 | 10.70 | 2.41 |
Current Ratio | 16.12 | 10.96 | 2.53 |
Interest Coverage | −138.69 | −5.27 | — |
Quick Ratio
PLRX
CBAY
DYN
Profitability
|
Metric
|
PLRX
|
CBAY
|
DYN
|
|---|---|---|---|
Return on Assets (Normalized) | −23.39% | −30.06% | −77.53% |
Return on Equity (Normalized) | −25.61% | −51.97% | −94.92% |
Return on Invested Capital (Normalized) | −29.08% | −30.87% | −88.19% |
Return on Assets
PLRX
CBAY
DYN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lnssqhcck | Xcrr | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rgjggrdc | Symfkcp | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qfvfhhnr | Hpfhtv | $108.2 Bil | |
MRNA
| Moderna Inc | Zkxjtnpz | Cmqb | $50.9 Bil | |
ARGX
| argenx SE ADR | Nqjnqypgh | Gzzby | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Jrpfjktdf | Yttpg | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tgyjggkn | Lcnvhp | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hxnhzhvkm | Jstsbbn | $14.6 Bil | |
INCY
| Incyte Corp | Zbdthhb | Bjcnfw | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xktzhvdbq | Tnbmtc | $12.3 Bil |